Vaxart, Inc. (NASDAQ:VXRT) Holdings Reduced by Sio Capital Management LLC

Sio Capital Management LLC lowered its holdings in Vaxart, Inc. (NASDAQ:VXRT) by 7.8% in the 3rd quarter, Holdings Channel reports. The firm owned 13,608,244 shares of the biotechnology company’s stock after selling 1,156,747 shares during the period. Vaxart accounts for 4.6% of Sio Capital Management LLC’s portfolio, making the stock its 5th biggest holding. Sio Capital Management LLC owned approximately 0.08% of Vaxart worth $11,553,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Mesirow Financial Investment Management Inc. boosted its holdings in Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 20,000 shares during the last quarter. Tidal Investments LLC purchased a new stake in Vaxart during the 1st quarter valued at $56,000. Sequoia Financial Advisors LLC purchased a new position in shares of Vaxart in the 2nd quarter worth $65,000. Monaco Asset Management SAM purchased a new stake in Vaxart during the second quarter valued at $402,000. Finally, Millennium Management LLC grew its stake in shares of Vaxart by 110.8% during the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock valued at $2,660,000 after purchasing an additional 2,095,274 shares during the period. 18.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Oppenheimer assumed coverage on shares of Vaxart in a report on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price objective on the stock.

Vaxart Trading Up 1.8 %

Shares of NASDAQ:VXRT opened at $0.61 on Friday. The stock has a 50 day moving average of $0.75 and a 200 day moving average of $0.76. Vaxart, Inc. has a 12-month low of $0.52 and a 12-month high of $1.54.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.